4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

Citigroup initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $95.00

Canaccord Genuity initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $89.00

BofA Securities initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $80.00

BTIG Research initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $43.00

TD Cowen initiated coverage of Apogee Therapeutics with a rating of Outperform

Wedbush initiated coverage of Apogee Therapeutics with a rating of Outperform and set a new price target of $40.00

Guggenheim initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $29.00

Stifel initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $34.00

Jefferies initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $29.00

Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025 APG279 (APG777 + APG990) Phase 1b head-to-head study vs. DUPIXENT supported by positive APG990 interim Phase 1 results, which exceeded trial objectives and demonstrated potential for three- and six-month dosing in combination with APG777; APG279 readout expected in second half of 2026 $731.1 million cash, cash equivalents and marketable securities with runway into Q1 2028 SAN FRANCISCO and BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company ad

Interim Phase 1 results for APG990, a novel half-life extended OX40L antibody, exceeded trial objectives and demonstrated an approximately 60-day half-life APG279 (APG777 + APG990) Phase 1b head-to-head study vs. DUPIXENT supported by successful completion of preclinical combination toxicology studies and positive APG990 interim Phase 1 results; trial planned to initiate this year with readout expected in second half of 2026 Webcast to be held today at 8:30 a.m. ET SAN FRANCISCO and BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in t

SAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report interim results from the Phase 1 APG990 healthy volunteer trial on Monday, March 3, 2025. Following the announcement, the Company will host a conference call and webcast at 8:30am ET to discuss the results and plans for i

SAN FRANCISCO and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE) today announced that members of management will participate at the following investor conferences. TD Cowen 45th Annual Health Care Conference Date: Tuesday, March 4, 2025Time: 2:30 p.m. ET Leerink Global Healthcare ConferenceDate: Tuesday, March 11, 2025Time: 8:40 a.m. ET A live and archived webcast of the fireside chats will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About Apogee Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled Part A 16-week proof-of-concept data anticipated in mid-2025 SAN FRANCISCO and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis (EoE) and other I&I indications, today announced the first patient has been dosed in the Part B portion of the Phas

SAN FRANCISCO and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), today announced that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 1:00 p.m. E.T. A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About Apogee Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, COPD, EoE and other I&I indications.

Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly versus monotherapy Preclinical proof-of-concept achieved for APG777 + APG333 combination with clinical trial planning underway in asthma and COPD SAN FRANCISCO and WALTHAM, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic

Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of biomarkers Data up to 12 months reinforce APG777's best-in-class potential, including 77-day half-life, and provide a potential path to annual dosing 16-week topline data from APG777 Phase 2 Part A trial in AD accelerated to mid-2025 based on strong enrollment Preclinical and coformulation proof-of-concept achieved for APG777 + APG990 combination Phase 1b head-to-head trial against DUPIXENT expected to initiate in 2025 with data in 2H 2026 Preclinical proof-of-concept achieved for APG7

SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced the agenda for its upcoming virtual R&D Day being held on Monday, December 2, 2024 at 10:00 a.m. ET. Featured Speakers:Members of the Apogee management team will be joined by key opinion leaders (KOLs) who will discuss the current landscape and need for new t

SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that it will host its virtual R&D Day at 10:00 a.m. ET on Monday, December 2, 2024. The event will include presentations from management discussing updates across Apogee's programs, highlighting APG777's best-in-class potential in AD, the significant role of

144 - Apogee Therapeutics, Inc. (0001974640) (Subject)

8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)

144 - Apogee Therapeutics, Inc. (0001974640) (Subject)

8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)

S-8 - Apogee Therapeutics, Inc. (0001974640) (Filer)

10-K - Apogee Therapeutics, Inc. (0001974640) (Filer)

SCHEDULE 13G - Apogee Therapeutics, Inc. (0001974640) (Subject)

144 - Apogee Therapeutics, Inc. (0001974640) (Subject)

8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)

144 - Apogee Therapeutics, Inc. (0001974640) (Subject)

SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced the agenda for its upcoming virtual R&D Day being held on Monday, December 2, 2024 at 10:00 a.m. ET. Featured Speakers:Members of the Apogee management team will be joined by key opinion leaders (KOLs) who will discuss the current landscape and need for new t

SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that it will host its virtual R&D Day at 10:00 a.m. ET on Monday, December 2, 2024. The event will include presentations from management discussing updates across Apogee's programs, highlighting APG777's best-in-class potential in AD, the significant role of

SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease and other I&I indications, today announced the appointment of Jeff S. Hartness as Chief Commercial Officer. Mr. Hartness has an extensive track record in commercial and corporate leadership, bringing more than 25 years of experience in the biotech industry focused on product launches, market access strategy,

SAN FRANCISCO and WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today announced that Lisa Bollinger, MD, has been appointed to the company's board of directors. Dr. Bollinger most recently served as Vice President, Regulatory Affairs, Global Regulatory Affairs and Clinical Safety (GRACS) at Merck, where she led the general medicine therapeutic area in regulatory affairs. Dr. Bollinger's over 30 years of experience in drug development,

SAN FRANCISCO and WALTHAM, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease and other inflammatory and immunology (I&I) indications, today announced the appointment of Mark C. McKenna as Chairman of its board of directors. Mr. McKenna's knowledge and successful track record in the I&I space as well as his significant development, commercial and executive management experience contributed to the Apogee board of directors' selection decision. "We are thrilled to welcome Mark as chair of our board and to

SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

SC 13G - Apogee Therapeutics, Inc. (0001974640) (Subject)

SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

SC 13G - Apogee Therapeutics, Inc. (0001974640) (Subject)

SC 13D/A - Apogee Therapeutics, Inc. (0001974640) (Subject)